New peptides B7-33 develop base on Relaxin-2 Antifibrotic treatment

What are B7-33 peptides?
https://www.astersteroids.com/new-peptides-b7- , 33-develop-base-on-relaxin-
2-
antifibrotic- , trea , tment-of-acute-heart-failure-and-myocardial-infarc ,
tion/
B7-33 is a functional selective Relaxin-receptor 1 agonist in development,
derived from the naturally occurring human hormone Relaxin-2.
Relaxin's peptides are structurally similar to insulin-like peptides in that
they consist of two chains of 53 amino acids, chain A and chain B, which are
connected by three disulfide bonds to function. This chemical structure
makes it difficult to recombine or chemically synthesize, so the researchers
determined its minimum active structure on the basis of Relaxin and
developed a single B-chain peptide analogue B7-33.
The name B7-33 derives from the fact that it contains these 27 residues
between 7-33 in the B-chain amino acids in Relaxin, hence the name B7-33.
Use of B7-33 peptides
B7-33 is the smallest active structure in Relaxin-2 and has similar effects
to Relaxin, such as vascular dilation, increased renal blood flow, increased
pumping volume in patients with acute heart failure without increasing
cardiac burden, rapid anti-inflammatory, anti-hypertrophy, anti-fibrosis,
etc. In the treatment of myocardial infarction, B7-33 induces a link between
mitogen-activated protein kinase signaling and the heart's unfolded protein
response after infarction, which has a protective effect against ischemia-
reperfusion injury after myocardial infarction and promotes pro-inflammatory
changes in the tissue during the early stages of infarct healing. B7-33 is
also expected to be used in the production of anti-fibrotic materials or
materials that resist foreign body reactions.

Minimum Order: 10 grams

Click to Enlarge